Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020.
Sara Jane CromerKristin M D'SilvaElaine W YuJoan LandonRishi J DesaiSeoyoung C KimPublished in: Journal of general internal medicine (2021)
Rates of denosumab use outpaced growth of all other bone-directed therapies over the past decade. Treatment rates after osteoporotic fractures were low and declined over time, highlighting major failings in osteoporosis treatment in the US.